Mostly Markets
Subscribe
Stocks/Health Care/Pharmaceuticals

Eli LillyLLY

Pharmaceuticals · Indianapolis, Indiana · In the S&P 500
High qualityPricier than peers
$1,417.54+3.19%After hours: $1,414.51 (−0.21%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 74.2% over 1 year
Eli Lilly over 1 yearDaily close, $, to 30 Oct 2026
$800$1,000$1,200Nov2026MarMayJulSep$1,418$1,000$1,250NovMarJul$1,418
Source: Nasdaq daily closes
Market value$1.33T
Price to earnings46.0x
Forward P/E36.3x
Dividend yield0.49%
Year to date+31.9%
One year+74.2%
Next earningsNot scheduled
SectorHealth Care
52-week range (closes)
$844.50$1,417.54

Quality and valuation

How Eli Lilly compares with other health care stocks. A description, not a recommendation.

Eli Lilly and 4 pharmaceuticals peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: stronger than mostValuation: pricier than most

A stronger business than most health care companies, priced above most of them.

Eli Lilly trades at 36.3 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew faster than the sector median: +45.5% vs +7.8%
  • Keeps more of each sale (gross margin): 83.6% vs 65.3%
  • Keeps more of its revenue as profit (net margin): 31.9% vs 9.7%
LLY trades at 36.3x forward earnings, above the sector medianForward p/e, Pharmaceuticals peers
BMY10.5xPFE11.1xNVO12.2xNVS17.0xAZN17.5xMRK18.1xJNJ25.1xLLY36.3xSector median 19.1xBMY10.5xPFE11.1xNVO12.2xNVS17.0xAZN17.5xMRK18.1xJNJ25.1xLLY36.3xSector median 19.1x
Source: CNBC quotes; Mostly Markets
At 46.0x earnings, LLY is cheaper than its average since Oct 2024Price over the last 12 months of reported (GAAP) diluted EPS
P/EUsual range (±1 s.d.)
40x60x80xAverage 55.8x2025202646.0x75xAverage 55.8x2025202646.0x
Source: Nasdaq prices; SEC filings

Financials

From Eli Lilly's SEC filings, through the quarter ending 30 Sep 2026. Hover or tap a bar for its value.

Revenue grew 38.6% from a year earlierQuarterly revenue, $bn, latest Q3 ’26
$0bn$10bn$20bnQ4 ’24Q2 ’25Q4 ’25$24.4bnQ3 ’26$0bn$10bn$20bnQ4 ’24Q2 ’25Q4 ’25$24.4bnQ3 ’26
Source: SEC filings
Growth slowed to +38.6% last quarterRevenue growth, year on year, %
0%20%40%Q4 ’24Q2 ’25Q4 ’2538.6%Q3 ’260%20%40%Q4 ’24Q2 ’25Q4 ’2538.6%Q3 ’26
Source: SEC filings
Diluted EPS was $7.22 last quarterQuarterly diluted earnings per share, $
$0$2$5$8Q4 ’24Q2 ’25Q4 ’25$7.22Q3 ’26$0$5Q4 ’24Q2 ’25Q4 ’25$7.22Q3 ’26
Source: SEC filings
Last 12 monthsLLYSector median
Revenue growth+45.5%+7.8%
Gross margin83.6%65.3%
Price to earnings46.0x30.2x

Stories on Eli Lilly

Saturday, 31 October
The Daily

Intel's Worst Day Since 1974 Capped the Nasdaq's Worst Month Since March 2025

Five big companies lost about a quarter or more of their value this week on soft outlooks, and the Nasdaq ended October down about 5.3%. The week in eight charts.

INTC▼ 28.6%
A collage of a cracked computer chip falling off a cliff made of red candlesticks
Thursday, 29 October
Earnings

Eli Lilly (LLY) Tops Q3 Estimates as Mounjaro Sales Jump 65%

Lilly's revenue rose 39% to $24.40 billion, beating the $22.61 billion expected, and it raised its 2026 sales forecast by $5.5 billion at the midpoint. The stock jumped 6.6% to a record close.

LLY▲ 6.6%
A collage of a giant medicine pen standing like a monument beside a staircase of green candlesticks

Similar companies

Pharmaceuticals, by market value.

CompanyPriceTodayYTDValue
JNJJohnson & Johnson$273.20−0.73%+32.0%$658B
MRKMerck$149.52+2.18%+42.0%$369B
NVSNovartis$160.79−0.19%+16.6%$327B
AZNAstraZeneca$186.65+7.02%+6.4%$290B
PFEPfizer$30.52+1.90%+22.6%$174B
NVONovo Nordisk$40.00+2.20%−21.4%$136B
BMYBristol Myers Squibb$62.48+1.78%+15.8%$128B
ZTSZoetis$79.72+1.85%−36.6%$32.94B